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Summary 
We present a review and analysis of the ethical considerations in off-label ketamine use for 
severe, treatment-resistant depression. The analysis of ethical considerations is contextualised 
in an overview of the evidence for ketamine use in depression, and a review of ketamine’s 
safety profile. We find that on current evidence, ketamine use for severe, treatment resistant 
depression does not violate ethical principles; however, clinicians and professional bodies 
must take steps to ensure that guidelines for good practice are enacted, that all experimental 
and trial data are made available through national registries, and that the risk potential of 
ketamine treatment continues to be monitored and modelled. We conclude with a set of key 
recommendations for oversight bodies that would support safe, effective and ethical use of 
ketamine in depression.  
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 “Arguably the most important discovery in half a century: ketamine produces rapid 
antidepressant action in treatment resistant depressed patients.” Duman & Aghajanian1   
 
Ketamine has thus been hailed as the major advance in the treatment of depression of the past 
50 years [1]. Numerous clinical trials have demonstrated that a single slow intravenous dose 
given over about 40 minutes produces a rapid decrease in depressive symptoms lasting from a 
few hours to 14 days [2] (see aan Het Rot   [3]  for a review).  All other existing 
antidepressant drug treatments have a therapeutic lag of 3-4 weeks and around a third of 
patients do not respond.   
 
The impressive antidepressant effects of ketamine have spurred a great deal of research 
interest, and there is also growing clinical use of ketamine for the treatment of depression. At 
present clinical use is “off-label”; no pharmaceutical company yet has a marketing 
authorisation. In addition, there is considerable recreational use of ketamine in certain 
countries [4],  which has led to repeated calls by some for tighter regulatory controls on 
ketamine [5].  
 
What is the evidence for the use of ketamine in depression? 
The first study to draw attention to ketamine as an antidepressant was a cross over study of 7 
patients with major depressive disorder in 2000 [6].  Six years later a study of 17 treatment-
resistant patients with Major Depressive Disorder [2]  found 71% of the participants to have a 
greater than 50% reduction in depressive symptoms within 24 hours of ketamine 
administration (0.5mg/kg iv infusion over 40 mins), while the same participants showed 
almost no change in symptoms following the placebo saline injection. Moreover, the response 
was sustained for the 1-week follow-up in approximately one-third of the participants.  
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In a  recent systematic review including 9 ketamine trials, ketamine was associated with 
higher rates of clinical response and remission relative to comparator (saline or midazolam) 
at 24h, 3 days  and 7 days [7]. However not all patients respond to ketamine and the duration 
of antidepressant effect is very variable across individuals.  Rapid reductions in suicidal 
ideation in depressed patients who received ketamine have been replicated [8, 9 ]. Other 
research has begun to evaluate the potential use of ketamine in palliative care settings, where 
the drug’s pain-reducing effects may provide an additional benefit alongside its 
antidepressant effects [ 10, 11] . 
 
Why is there concern about the use of ketamine for depression? 
Ketamine abuse has been associated with a range of negative long-term side effects, which 
studies suggest are confined to daily users  [12 ]. The most serious of these side effects is 
ketamine-induced ulcerative cystitis or ‘ketamine bladder’ ( [13,14] . This is a recently 
identified condition characterised by extremely painful and frequent urination that seems to 
have severe and potentially long lasting impacts on the patient [15]. However, drug users who 
take ketamine less than daily have not reported, and show no evidence of ‘ketamine bladder’.  
One case of ketamine-associated cystitis associated with chronic pain management has been 
reported [16].  
  
A key difference in clinical as opposed to recreational use of ketamine is the dosage and 
frequency of use. Tolerance develops rapidly to ketamine, and in anaesthetic practice, is 
termed tachyphylaxis. Frequent recreational users will compensate for this by increasing the 
dosage used over time such that doses of several grams per day, rather than milligrams, are 
consumed, and these are generally ‘snorted’ through the nose in a similar way to cocaine4.   
[4] In contrast, medical use in depression would generally be a single 35mg dose for an 
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average weight adult given intravenously, which could be repeated at the same dosage days 
or weeks later. Although an intranasal formulation is currently in development for the 
treatment of depression31  [17] this would again be at very small doses compared to those 
used recreationally. Dose level and frequency are related to risk of hepatotoxicity, with 
higher risk in prolonged infusion or frequent dosing in therapeutic contexts [18]. 
	
  Patients with psychosis given an acute dose of ketamine in the lab experienced a resurgence 
of their individual psychotic symptoms that in some was protracted, lasting up to 1 week. [19] 
This work clearly provoked ethical concerns and no further challenge studies were conducted 
with patients with schizophrenia. Additionally, to demonstrate the safety in patients without 
schizophrenia, a review examining psychotomimetic phenomena across studies involving a 
total of 450 volunteers given similar doses of ketamine found only 6 incidences of such 
mental states that were unpleasant enough to require the infusion to be stopped, all of which 
remitted completely in the hours following the cessation of the infusion [20].  
 
What are the ethical issues surrounding the use of ketamine in depression? 
Ketamine use for severe depression motivates a complex set of ethical concerns. The very 
limited existing literature on the ethics of ketamine use for depression has highlighted some 
of these, covering clinical ethics, research ethics and health policy35-40. [21-30] The authors of 
these papers agree on three primary ethical concerns: genuine need for treatment of patients 
with severe, treatment-resistant depression; lack of safety and efficacy data in off-label use of 
ketamine; and the abuse potential of ketamine.   
 
Clinical experience raises further issues that pose practical and ethical challenges for 
clinicians; these challenges have not been well documented in the literature to date. 
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Clinicians must be concerned about the potential of illegal diversion or self-treatment with 
illegally obtained drugs; and they face uncertainty given the lack of a proven strategy to 
maintain a beneficial effect of ketamine. Patients who experience a dramatic beneficial 
response to ketamine may face a serious fall in morale following rapid relapse; and suicidal 
patients may be harmed by the false reassurance of an abrupt, but potentially brief, reduction 
in suicidality. Severe and unmonitored side-effects could lead to early discontinuation of an 
otherwise promising treatment. Finally, ketamine can seem attractive to those who would 
rather try a drug of abuse than a ‘conventional’ antidepressant, due to stigma attached to 
psychiatric drug treatments [31].   
 
 For the more cautious authors, these concerns are sufficiently serious to constitute reasons to 
avoid clinical use of ketamine in depression. [24, 27, 30].  Other authors take a more 
moderate position, but highlight the need for judicious reporting of experimental findings and 
prudent professional decision-making in the absence of evidence-based guidance [22, 23, 28]. 
Professional judgment and integrity are particularly relevant with regard to the need for 
careful and consistent monitoring of patients treated with ketamine [22]. Authors writing 
from a US perspective have, on the one hand, criticised the restrictions on research on 
controlled substances for clinical use [26] and, on the other, expressed strong concerns about 
the availability of ketamine in commercial clinics [23, 25]. 
 
As the available literature elaborates, lack of scientific knowledge about ketamine treatment 
in depression means that off-label clinical use entails significant uncertainty. This 
uncertainty, and the potential for misuse of ketamine, pose risks of harm to patients and 
clinicians, and to society. At the same time, the need for further treatments in depression is 
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clear, and the frustrating rate at which new drugs move from bench to bedside means that off-
label use of ketamine is currently increasing [21]. 
 
A relevant ethical analysis must identify as primary challenges the recognition of patient need 
on the one hand, and the risks of harm posed by lack of scientific knowledge and the abuse 
potential of ketamine, on the other. However, there should be a further recognition that 
patient need and the potential for harm can pull in opposite directions in clinical decision-
making. An ethical analysis must do more than describe the harms and benefits of treatment; 
it should provide clinicians with some guidance about how to balance these opposing ethical 
forces.  
 
In what follows, we draw on a recent framework for ethical use of novel therapeutics41  [32] to 
argue that ketamine use in depression presents an exceptional case for clinical application 
ahead of further trial evidence. Drawing on the ethical framework and the literature, we next 
consider the balance of patient need and the potential for harm in this case. We propose three 
key interests at stake in this balance: autonomy, innovation and professional integrity. After 
outlining these interests, we make recommendations to support ethical clinical use of 
ketamine off-label for severe, treatment-resistant depression. 
 
Nuffield Council on Bioethics: Report on Novel Neurotechnologies 
As a foundation for its ethical guideline, the UK Nuffield Council on Bioethics (NCOB) 
recognized six principles of responsible research and innovation specific to novel 
neurotechnologies.  
Box 1: Six Principles of Responsible Research in Novel Neurotechnologies 
• Clearly identified need 
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• Securing safety and efficacy 
• Generating robust evidence 
• Continuous reflexive evaluation 
• Coordinated interdisciplinary action 
• Effective and Proportionate Oversight 
 
We propose that these principles are relevant to the ethical use of ketamine for depression, in 
so far as the Report covers novel therapeutics for mind and brain that are still in an 
experimental phase of development. Alongside these principles, the NCOB Report recognizes 
that innovation in psychiatric therapeutics is a societal good given the lack of effective 
treatments for severe, chronic mental disorders. Below we consider arguments for, and 
challenges to off-label ketamine use in depression through the lens of the NCOB core 
principles. 
 
Clearly Identified Need 
Severe depression is an illness causing significant impairment in patients’ ability to function 
and to lead flourishing lives. Moreover, patients’ suffering has negative consequences within 
families, communities and the workplace representing a vicious circle that can involve 
stigma, shame and guilt. The impacts of this vicious circle are amplified if a patient loses the 
ability to work, which further diminishes dignity and a sense of personal and social value in 
patients [33]. 
 
The literature on depression treatment suggests that 30% of patients are treatment-resistant 
[34]. Many of these patients will respond to augmented treatments, but a quarter of these 
patients will respond inconsistently or not at all [35]  Treatment-resistant depression poses a 
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significant clinical challenge. The treatment of most value in treatment-resistant depression, 
electro-convulsive therapy (ECT), involves inducing seizures. Many patients are unwilling to 
undergo this treatment because of fears of memory loss, as well as general stigma about ECT.  
[36 ]. The need for intervention is great: Severe depression is associated with higher risk of 
suicide [37].  Suicidal ideation is difficult to manage without effective treatment, and the 
struggle to find effective treatments may itself exacerbate suicidal thinking.  Ketamine	may	
rapidly	reduce	suicidal	ideation	 [38].  The problem of rapid relapse following this beneficial 
response needs to be carefully clinically managed.	
 
Constitution of Robust Evidence for Safety and Efficacy of Ketamine Treatment in 
Depression 
 
Ketamine can be used off-label for treatment of depression because it is already a licensed 
drug. Off-label use of medicines is common across medical specialties ([39] but it is 
particularly high in psychiatry, due in part to lack of licensed treatments for many DSM-5 
conditions [40].  The precedent for off label prescribing across affective disorders is now 
significant - 45% of antidepressant prescriptions are for conditions other than depression 
[41].  The important difference is that the treatment effects of antidepressants are much better 
understood than those of ketamine in patients with depressive disorders.  
 
No matter how widespread, off-label use of medicines does not constitute a sound reason to 
endorse off-label ketamine use in depression. A primary challenge in off-label drug treatment 
is that a drug’s efficacy, dosing and side effects are interpreted largely through clinical 
experience and case study reports, rather than through the ‘gold standard’ evidence provided 
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by clinical trials. Lack of trial data on a drug for a specific condition increases concerns about 
the potential harms of treatment.  
 
In the case of ketamine treatment for depression, preliminary trial data is available, as 
outlined above, and further trials are underway. However, some have argued that existing 
trial data on ketamine use in mood disorders should not be regarded as meeting a high 
standard of evidence due to methodological and other flaws and that clinical use of ketamine 
for depression should wait for the outcome of more robust trials  [29]. 
 
However, RCTs do not provide the observational evidence necessary to understand how 
patients interact with treatments outside the rigours of the RCT process [42]. This knowledge 
is particularly important in the case of a drug with high misuse potential. In addition, RCTs 
have high internal validity but low external validity: by design, trials enroll homogeneous 
patient populations that represent a narrow band of the diversity present in a complex, 
heterogeneous medical population, such as patients with depressive disorders. [43]. 
One way to improve the low external validity problem of RCTs is to do more RCTs, with 
diverse patient populations. Several RCTs for ketamine use in depression are currently 
recruiting [44].  However, ketamine is a generic drug, and continuous industry or public 
investment in a significant number of expensive trials is unlikely. Such trials are required to 
assess the potential doses, routes, regimes, predictive factors and drugs that may maintain the 
benefit of ketamine in depression. RCTs also take a long time, which patients with severe 
treatment-resistant depression might not have.  
 
Given this context, observational and single case studies of ketamine use in depression should 
arguably be encouraged as part of a commitment to robust science and to patient need, as a 
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necessary adjunct to the RCTs, and as an independently valid and valuable source of 
evidence for treatment safety and efficacy [45]. In order to achieve maximum benefit, these 
cases should be registered and carefully monitored, and all data should be transparently 
shared with professional and patient groups (subject to criteria for data privacy). 
 
One might agree with the most of the arguments above and still advocate for a delay on 
ketamine use in the clinic until better trial data is available. To address the needs of 
treatment-resistant patients at high risk of suicide while trials are ongoing, one might propose 
compassionate use access to ketamine as an option [46]. However, the delay-advocacy 
position ignores the reality that ketamine is quite easily available commercially in 
independent clinics and on the black market. Such outlets will provide ketamine to severely 
depressed patients quickly, most likely without establishing a robust patient profile and 
without registering and monitoring outcomes. 
 
Our analysis thus far suggests that there is a principled case for professional, clinical 
provision of ketamine treatment off-label, to patients with severe, treatment-resistant 
depression. In the next section, we test the case against a set of key interests that apply in 
weighing up the balance between patient need and the potential for harm in off-label clinical 
use of ketamine for depression. 
 
Balance of patient need and potential for harm in ketamine treatment for depression: 
Key interests 
Autonomy 
A general definition of autonomy in medical ethics addresses the capacity to independently 
reflect and decide upon a set of choices, on the basis of factors that feel authentic to the 
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individual. This account of autonomy assumes a process of self-reflection that eventually 
identifies a set of authentic (to the person) desires [47]. As described above, severe 
depression can undermine the exercise of autonomy, because, for example, low self-worth or 
a lack of volitional agency compromise identification of authentic desires [48] . These 
cognitive features may be cause or consequence of depression, but without effective 
treatment of the condition, autonomy capabilities could continue to diminish, sometimes to 
the point that a patient will no longer find his/her life worth living. Protection of autonomy in 
the treatment of severe depression is therefore both an ethical duty (to ensure that patient 
autonomy is not threatened by the process or outcomes of treatment) and a clinical goal 
(treatment promotes or restores patient autonomy).  
 
If there is a reasonable expectation that harmful side effects of treatment can be managed, 
then a patient’s expressed desire for treatment – which is an expression of autonomy interests 
- must carry weight in the decision-making process. Indeed, a severely depressed patient who 
requests ketamine treatment can be viewed as exercising autonomy interests that require 
protection because the diminishment of patient autonomy poses a risk to the life of the 
depressed patient. Therefore the moral duty to provide ketamine treatment when a depressed 
patient requests treatment can be seen to have special force that might outweigh some other 
considerations.  
 
However, a patient can only be viewed as exercising autonomy if the patient receives 
sufficient information to make an informed decision about off-label ketamine treatment. [49]. 
The value of consent is diminished if sufficient information is not available, and it is null if 
the patient lacks capacity or is coerced [50].  The criteria for consent to experimental 
treatment with ketamine must be carefully considered, due to lack of RCT evidence to inform 
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an analysis of the harm/benefit ratio, and, relatedly, patients’ inability to evaluate the harms 
of potential side effects. However, as we note above, the combination of clinical experience 
and available trial data arguably provides sufficient information for valid patient consent. 
 
The capacity of severely depressed patients ‘desperate for treatment’ has also been 
questioned [29], but this conflates two different issues: distress and capacity. The distressed 
drive of a desperate, depressed patient to seek relief for their psychic pain is not, of itself, 
indicative of loss of capacity. The distress may or may not interfere with the ability to take in 
and properly weigh up information about the risks and benefits of a new treatment. 
Depression creates a negative cognitive bias than can undermine balanced judgment [51].  
Severely depressed patients are more usually indecisive and cautious than recklessly risk-
taking. [52]. It is this indecisiveness, rather than the patient’s desperation, that more 
frequently creates a dilemma for clinician caring for a severely depressed patient. The levels 
of agency in the relationship are, by definition, highly asymmetric. A balanced presentation 
of the evidence, and of medical ignorance, can support patient decision-making; but 
clinicians must guard against the harms of excessive paternalism that are an evitable risk in 
the doctor-patient relationship [53].      
 
Such challenges to information and consent in depression treatment and, by extension, to 
patient autonomy interests are not unique to ketamine; they exist in relation to another 
experimental psychiatric treatment for severely depressed patients: deep brain stimulation 
(DBS) [54].  In the case of ketamine, as with DBS, the particular challenges around consent 
can be addressed initially through acknowledgement of these risks, institutional review of 
consent processes (in the case of research), and a commitment to ongoing monitoring and 
evaluation of patients. [32].  In practice, signed confirmation that detailed, up to date, written 
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information has been received would meet this need. The information provided to patients 
should be explicit about the lack of current information on the strategies for maintaining any 
acute benefit and the paucity of data on long term risks.   
 
When patients with capacity want to pay for a trial of ketamine, which they understand has an 
undefined and possibly small chance of benefit, the distinction between acute and chronic 
treatment is a crucial consideration in the avoidance of harm. The acute risks of medical 
ketamine are well known; many patients experience dose-dependent acute effects. Very few 
patients, if any, experience long term sequelae of treatment. What evidence there is of longer 
term medical oral or intravenous [55] use is relatively reassuring [56]. 
 
Further strategies to ensure best practice in relation to consent should be considered: An 
interval between the consultation and first treatment allows a period for reflection and 
discussion with family and carers. The presence of a friend or relative in the consultation to 
act as an advocate can be helpful. As ever, the clinician must ensure that the decision-making 
process enables the patient to make an informed, autonomous decision. 
 
Such processes cannot remove the risks inherent in this experimental treatment. However, in 
respect of patients’ autonomy interests it is important to recognize that paternalism cuts both 
ways. We should not err on the side of paternalistic precaution when weighing up the balance 
of need and potential for harm in ketamine treatment. 
 
Innovation 
Innovation that leads to better tolerated, more effective therapies for chronic mental illness 
benefits patients, families and clinicians, has important public health benefits and reduces the 
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societal impacts of mental illness [32]. For these reasons, innovation is a key interest in the 
balance of patient need and the potential for harm; and the precautionary principle should not 
operate a priori in a way that stifles innovation. This is to say that the potential harms of 
ketamine must be managed in such a way that allows the innovative potential of ketamine use 
in severe depression to be tested. Indeed, the innovative potential of ketamine-related 
compounds has been recognized by the FDA for both treatment resistant depression and for 
major depression with imminent risk of suicide [57].  
 
Innovation to address the problem of treatment-resistance necessarily includes innovation in 
the pathways to clinical use of a particular intervention. We have already outlined some of 
the limitations of the conventional RCT pathway. It is also worth noting that, if access to 
ketamine were restricted to those involved in clinical trials, very few patients would receive 
it, creating unequal conditions, particularly for patients in low resource settings and those 
with limited access to clinical trials [58].  Therefore off-label use of ketamine for treatment-
resistant depression in single cases can contribute to innovation and to justice, if the harms of 
ketamine use can be minimized, and the benefits maximized, in the form of systematic and 
transparent data recording and sharing. 
 
Misuse Potential 
Innovation in treatments includes innovation in treatment delivery technologies. Most trials 
have used a low dose (typically 0.5mg/ml) of intravenous ketamine, but a wide variety of 
other routes (oral, sublingual/transmucosal, subcutaneous and intranasal) have been reported.   
These alternatives have the potential benefit that they are less invasive and can be self-
administered by the patient outside the clinic, thereby promoting patient autonomy and, 
possibly, compliance in treatment. However, this is potentially at the price of greater abuse 
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potential. As with analgesia and breakthrough pain, the use of progressively higher and more 
frequent doses to avert relapse is inevitable if the patient has access to large supplies. Such 
addiction and abuse would not only undermine good treatment outcomes. It would also 
potentially add fuel to the global black market in ketamine [4] either through illegal diversion 
or, more likely, by patients pursuing illegal routes to access the drug if their physicians refuse 
to prescribe it. 
 
At the same time, it is important not to confuse the desire to continue taking a drug which 
treats chronic symptoms which reemerge when the drug is stopped, with the craving of 
addiction: paracetamol can be used repeatedly to treat a chronic pain; the dialysis patient feels 
better after each exchange. 
 
There is already wide experience of successful use of long term oral ketamine without such 
tolerance or tachyphalaxis [59, 60].  For example, daily dosing with oral ketamine (eg 
150mg) has been used successfully in the context of pain. However, as the interval between 
ketamine doses declines, so the potential for addiction increases. So far, there are just two 
case reports. In one, intranasal ketamine was prescribed for depression at a dose of 75-150mg 
intranasally 4 hourly as needed [23] was poorly monitored  and was being used 10-12 times 
daily with clear evidence of intoxication. In the other [61], intravenous ketamine (0.5mg/kg) 
was administered on alternate days for two weeks with evidence of emergent craving.   
 
The experience of using oral ketamine, benzodiazepines, oral opiate analgesia and methadone 
all offer potential models for successfully managing the addiction potential: short courses, 
prescriptions for small quantities, regular review, dosing intervals of at least 3 days, directly 
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observed therapy. Nevertheless, innovation in the development of ketamine and metabolite-
related compounds should prioritize lowering the abuse potential of ketamine [62]. 
 
Dependence is unlikely to occur in the context of clinical trials. Thus, careful prospective 
monitoring of a real world experience is essential to identifying the incidence of misuse and 
dependence. Professional guidelines detailing harm minimization strategies should not reject 
use of ketamine out of hand on the basis of risk; instead, they must achieve a balance between 
the benefits of innovation and patient autonomy on the one hand, and the potential for harm 
on the other. In the next section, we outline a set of harm minimization strategies and 
recommendations pertinent to the case of off-label use of ketamine for depression. 
 
Harm Minimisation: Strategies and Recommendations 
Professional Virtue and Integrity 
Health professionals carry responsibility for assessment of patient need, and for the decision 
to experiment with ketamine treatment. In the absence of evidence and guidelines, and in 
light of the potential for individual and societal harm associated with ketamine treatment, a 
great deal of ethical weight rests on the virtue qualities of the clinician [32]  The NCOB 
Novel Neurotechnologies Report identified three virtues of particular importance in the 
context of novel neurotechnologies: inventiveness, humility and responsibility:  
 
Box 2: Three Virtues 
• Inventiveness – expressed through technological innovation and by identifying ways 
of providing wider access to therapies.  
• Humility – acknowledging the limits of current knowledge and of our ability to use 
technologies to alleviate the harms of brain disorders.  
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• Responsibility – shown by robust research and clinical practices and by avoiding 
hype in communication about their potential uses.  
 
In the context of ketamine treatment for depression, inventiveness requires a degree of 
clinical experience and expertise that enables sound and reasoned decision-making under 
conditions of risk and uncertainty. Humility means the ability to make clinical decisions 
based in the best interests of the patient, without intrusion of personal interest or ambition. 
Responsibility denotes a clinician who will contribute to improving the research knowledge 
base about ketamine use for depression, and who will not make undue claims for ketamine 
treatment.  
 
These three virtues also reinforce the ethical principle of continuous reflexive evaluation. 
It is in the interest of professional bodies to support the education and development of these 
essential virtuous qualities of clinicians who administer ketamine treatment for depression, 
and to promote the principle of reflexive evaluation of clinical practice in this context. For 
example, in their discussion of the availability of ketamine use for depression in the United 
States, Sisti et al. [23] point out that private clinics use potentially coercive financial 
incentives to attract and maintain ketamine patients as active users, such as offering the 
patient a $500 rebate after the first six ketamine infusions. Such behaviours diminish public 
trust in treatment innovation, and thereby hurt patients in extreme need, as well as the health 
professionals who manage their care. 
 
Recommendations for monitoring and regulation 
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As we have outlined above, the increasing off-label use of ketamine for depression in the 
absence of long term safety data raises complex ethical challenges that urgently require a 
reasoned response. In developing recommendations of monitoring and regulation of ketamine 
use in depression, we embed the principle of proportionate oversight, and we aim to 
structurally integrate the principles of continuous reflexive evaluation and interdisciplinary 
action. We emphasise the need for an approach that views clinical guidance in this case as a 
dynamic process, in which guidance is systematically reviewed and updated as clinical 
evidence accumulates through transparent reporting of cases. We also underline the need for 
professional bodies and oversight bodies to work together to ensure high ethical standards in 
off-label ketamine use in depression.  
 
We consider it unlikely that the dangers of ketamine use would justify a different regulatory 
response to, say, short acting benzodiazepines such as lorazepam. Our analysis suggests that 
such off-label use can be ethical and it is important that any monitoring and regulation 
strategies are proportionate, and should not stifle innovation in treatment development, or 
threaten the interests of patient autonomy and professional virtue and integrity. On the other 
hand, if this were a new drug, the manufacturer would usually collect safety data from open 
label extensions of the licensing clinical trials.  Therefore we underline the importance of 
reporting on clinical practice and monitoring of outcomes. There is a risk that, if 
unmonitored, the risks of dependence and of cognitive, urological and other damage will go 
unquantified.   
 
Drawing on the literature and the analysis above, we propose a set of key action points for 
oversight bodies in Box 3 below.  
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BOX 3: KEY ACTIONS FOR OVERSIGHT BODIES (e.g. US Food and Drug 
Administration; European Medicines Agency; Professional Societies) [63]   
	 21	
 
1. Professional bodies should provide guidance to ensure that ketamine treatment 
for depression and other affective disorders conforms to high ethical standards. 
Such guidance should include: 
i. Publication of dynamic good practice guidelines for ethical use of ketamine for 
depression, which are continually updated based on reviews of new data: 
a. Provide guidance on the maximum quantity of intranasal, oral, or 
sublingual ketamine that can be supplied to patients to take at home, 
and/or the maximum interval between reviews by the prescriber. 
b. A statement that, before initiating a trial of ketamine, patients should be 
informed about, and encouraged to consider all viable, licensed options for 
treatment 
c. Recommendations on whether written consent should be required  
d. An example of content of a patient information sheet 
e. Require contribution to national registries of structured data on the safety 
and efficacy of repeated doses of ketamine  
2. Professional bodies, together with national institutions, e.g. US Food and Drug 
Administration (FDA); European Medicines Agency (EMA); UK Medicines and 
Healthcare Products Regulatory Agency (MHRA) should evaluate the need for 
Risk Evaluation and Mitigation Strategies (REMS,) to minimize risk of off-label 
ketamine in depression and to maximize benefits [64, 65].   
3. National institutions, e.g. FDA, EMA ,MHRA should support development of the 
international evidence-base on safety and efficacy in ketamine treatment for 
depression: 
i. Develop and maintain national registries to share trial information and safety 
and efficacy data; and to report data from single case studies: 
a. National registries should be linked up through an international network. 
They may be hosted by existing structures such as the US Prescription 
Drug Monitoring Program (PDMP)    [66, 67]   
b. Publish recommendations on any governance procedures, including 
suggestions for oversight procedures in institutions supporting ketamine 
clinics 
c. Support research to investigate the use and abuse potential of ketamine in 
depression; and to model the impacts of diverse risk management policy 
pathways on patient need, medical use, and societal harms 
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Conclusions 
The balance of risk and benefit is such that new restrictions around the use of ketamine for 
depression are not needed. However, those prescribing it should have a heightened degree of 
humility and responsibility. This will help to prevent the current promising development from 
being stopped or delayed by clinical mistakes which may increase policymakers’ concerns 
about the drug and decrease public trust [23, 31]. While our focus has been to provide ethical 
analysis and guidance for off-label clinical use of ketamine for depression, many of the 
ethical concerns we identify are broadly relevant to ketamine treatment in the context of 
research.    
 
At present, clinicians should advise patients that knowledge about ketamine treatment is 
limited. The key information that is needed to enhance the ethical use of ketamine for 
affective disorders is structured long term, naturalistic data on the safety of, and incidence of 
abuse of repeated dosing. This should be managed by national registries. Routine submission 
of data to such registries should be expected of all clinics. Efficacy trials of strategies for 
maintaining initial benefit are also required.   
 
In the meantime, we hope that the recommendations proposed here go some way to enabling 
innovative use of ketamine for treatment-resistant depression to continue, with appropriate 
care, precaution and foresight.  
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